JCO Precision Oncology Conversations podcasts features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they examine groundbreaking research in the world of precision oncology and learn how these advancements are redefining treatment protocols.
The year's fellows summarize the top JCO Precision Oncology articles in the series, JCO PO Article Insights.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
This JCO PO Article Insights episode delves into the Exonerate Trace assay, an optimized liquid biopsy leveraging circulating microRNAs to predict and dynamically monitor resistance to anti-EGFR therapies in metastatic colorectal cancer. It highlights how this assay offers improved predictive accuracy over traditional markers like CEA and CA99, providing a potential three to six-month lead time for detecting resistance. The discussion also covers the assay's development, its clinical implications for personalized real-time treatment decisions, and necessary future research for clinical integration.
JCO PO author Dr. Tejas Patil at University of Colorado Cancer Center shares insights into the JCO PO article, " CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions ". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210). LINK TO FULL TRANSCRIPT...
In this JCO PO Article Insights episode, host Carolyn Lineen summarizes the article, " Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis " bySwanton et al. LINK TO FULL TRANSCRIPT
In this JCO PO Article Insights episode, host Jordan Goldstein summarizes the article, "Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation" by Baden et al. TRANSCRIPT Jordan Goldstein: Hello, and welcome to JCO Precision Oncology Article Insights . I'm your host, Jordan Goldstein from Stanford Univers...
In this JCO Precision Oncology Article Insights episode, host Dr. Carolyn Lineen summaries the article, " Concordance of Oncotype DX Breast Recurrence Score Assay Results Between Paired Core Needle Biopsy and Surgical Excision Specimens in Hormone Receptor Positive, HER2-Negative Early-Stage Breast Cancer ," by Nassar et al. TRANSCRIPT Carolyn Lineen: Hello and welcome to JCO Precision Oncology Article Insights . I'm your host, Carolyn Lineen, from St. James's Hospital, Dublin, and today we will...
JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, " Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast. " Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitor...
In this JCO Precision Oncology Article Insights episode, host Dr. Jiasen He summaries the article, " Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors ," by Hassoun et al. TRANSCRIPT Jiasen He: Hello, and welcome to the JCO Precision Oncology Article Insights . I'm your host, Jiasen He, and today, we'll be discussing the JCO Precision Oncology article, " Longitudinal Evaluation of Circulating Tumor DNA as a Prognos...
JCO PO author Dr. Wainberg at UCLA shares insights into the JCO PO article, "Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial." Host Dr. Rafeh Naqash and Dr. Wainberg discuss how FGFR2b prevalence was similar across geographic regions and within defined patient and sample variables regardless of the level of expression. TRANSCRIPT TO COME
In this JCO Precision Oncology Article Insights episode, host Dr. Harold Nathan Tan summarizes " Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study " by Worden et al. TRANSCRIPT Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights , where we explore research that is reshaping our understanding of cancer therapeutics. I'm your host, Harold Nathan Tan, and today's epis...
JCO PO author Dr. Shilpa Gupta at Cleveland Clinic Children's Hospital shares insights into her article, " Fibroblast Growth Factor Receptor 3 (FGFR3) Alteration Status and Outcomes on Immune Checkpoint Inhibitors (ICPI) in Patients with Metastatic Urothelial Carcinoma ". Host Dr. Rafeh Naqash and Dr. Gupta discuss how FGFR3 combined with TMB emerged as a biomarker that may be predictive for response to ICPI in mUC. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Convers...
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes " Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized " by Góes et al. published on September 10, 2025. TRANSCRIPT Natalie DelRocco: Hello and welcome to JCO Precision Oncology Article Insights . I'm your host, Natalie DelRocco, and today we will be discussing the editorial " Genomic Risk Classifiers in Localized Prostate Cancer: Precise but Not Standardized ." This editorial by G...
Authors Drs. Jessica Ross and Alissa Cooper share insights into their JCO PO article, " Clinical and Pathologic Landscapes of Delta-Like Ligand 3 and Seizure-Related Homolog Protein 6 Expression in Neuroendocrine Carcinomas " Host Dr. Rafeh Naqash and Drs. Ross and Cooper discuss the landscape of Delta-like ligand 3 (DLL3) and seizure-related homolog protein 6 (SEZ6) across NECs from eight different primary sites. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversat...
In this episode of JCO PO Article Insights, host Dr. Jiasen He summarizes the article, " Somatic Mutation Profiles of Colorectal Cancer by Birth Cohort " by Gilad, et al published October 11, 2025. TRANSCRIPT Jiasen He: Hello, and welcome to the JCO Precision Oncology Article Insights . I am your host, Jiasen He, and today, we will be discussing the JCO Precision Oncology article, " Somatic Mutation Profiles of Colorectal Cancer by Birth Cohort ," by Dr. Gilad and colleagues. Early-onset colorec...
JCO PO author Dr. Bryson Katona at the University of Pennsylvania Perelman School of Medicine shares insights into his article, " Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium " Host Dr. Rafeh Naqash and Dr. Katona discuss how, given differing guidelines as well as lack of detail about how PC surveillance should be performed, approaches to PC surveillance across centers often differs. TRANSCRIPT Na...
JCO PO author Dr. Asaf Maoz at Dana-Farber Cancer Institute shares insights into article, " Causes of Death Among Individuals with Lynch Syndrome in the Immunotherapy Era ." Host Dr. Rafeh Naqash and Dr. Maoz discuss the causes of death in individuals with LS and the evolving role of immunotherapy. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations , where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO art...
In this JCO Precision Oncology Article Insights episode, Dr. Jiasen He summarizes JCO PO article " Synthetic Lethal Co-Mutations in DNA Damage Response Pathways Predict Response to Immunotherapy in Pan-Cancer " by Hua Zhong et al. TRANSCRIPT Jiasen He: Hello and welcome to the JCO Precision Oncology Article Insights . I am your host, Jiasen He, and today we will be discussing the JCO Precision Oncology article, " Synthetic Lethal Co-mutations in DNA Damage Response Pathway Predict Response to Im...
JCO PO authors Dr. Abhishek Tripathi and Dr. Salvador Jaime-Casas at City of Hope Comprehensive Cancer Center share insights into their article, " Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma ." Host Dr. Rafeh Naqash and Drs. Tripathi and Jaime-Casas discuss a novel understanding of the genomic alterations underlying SCBC, revealing actionable mutations that could serve as potential targets for improv...
In this JCO PO Article insights episode, Dr. Jiasen He summarized the JCO PO article " Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes " by Connolly et al. TRANSCRIPT Jiasen He: Hello, and welcome to JCO Precision Oncology Article Insights . I'm your host, Jiasen He, and today we'll be discussing the JCO Precision Oncology article, " Mucin 16-Directed Therapy in Pediatric Sarcomas: Case E...
JCO PO author Dr. Alison M. Schram at Memorial Sloan Kettering Cancer Center shares insights into her JCO PO article, " Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors ." Host Dr. Rafeh Naqash and Dr. Schram discuss relevant genomic and clinical features of patients with BRCA-altered uterine sarcoma and the efficacy of PARPis in this population. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations , wher...
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes " Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma " by Roelof van Ewijk et al. published on May 29, 2025. TRANSCRIPT Natalie Del Rocco: Hello, and welcome to JCO Precision Oncology Article Insights . I'm your host, Natalie DelRocco, and today we will be discussing the original report, " Prognostic Value of the G2 Expression Signature and MYC Overexpress...
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes " Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma " by Roelof van Ewijk et al. published on May 29, 2025. TRANSCRIPT Natalie Del Rocco: Hello, and welcome to JCO Precision Oncology Article Insights . I'm your host, Natalie DelRocco, and today we will be discussing the original report, " Prognostic Value of the G2 Expression Signature and MYC Overexpress...
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes " Real-Time Monitoring in Renal Cell Carcinoma With Circulating Tumor DNA: A Step Forward, but How Far? " by Zeynep B. Zengin et al. published on February 28, 2025. TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Natalie DelRocco: Hello, and welcome to JCO Precision Oncology Article Insights . I'm your host, Natalie DelRocco, and today we will be discussing the editorial, " Real-Time ...
JCO PO author Dr. Philip Philip at Henry Ford Cancer Institute and Wayne State University shares insights into his JCO PO article, " Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group ." Host Dr. Rafeh Naqash and Dr. Philip discuss how prospective trials are required to clarify the role of ctDNA as a valid surrogate end point for progression-free or overall survival in GI cancers. Tra...
In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes "Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma" by Dr. Miles C. Andrews, et al. published on June 07, 2024. Transcript The guest on this podcast episode has no disclosures to declare. Jiasen He: Hello and welcome to the JCO Precision Oncology Article Insights . I'm your host, Jiasen, and today we'll be discussing the JCO Precision O...
JCO PO author Dr. Dean A. Regier at the Academy of Translational Medicine, University of British Columbia (UBC), and the School of Population and Public Health, BC Cancer Research Institute shares insights into his JCO PO article, "Clinical Effectiveness and Cost-Effectiveness of Multigene Panel Sequencing in Advanced Melanoma: A Population-Level Real-World Target Trial Emulation." Host Dr. Rafeh Naqash and Dr. Regier discuss the real-world clinical effectiveness and cost-effectiveness of multig...
In this JCO PO Article Insights episode, host Harold Tan summarizes Low Kynurenine Levels Among Exceptional Responders on Phase Ib Trial of the HDAC Inhibitor Abexinostat with Pazopanib by Tsang et al, published November 07, 2024. Transcript Harold Nathan Tan: Welcome to JCO Precision Oncology Article Insights , where we explore cutting-edge discoveries in the world of cancer treatment and research. I'm Harold Nathan Tan, your host, and today we're taking a focused look at a compelling phase Ib ...
JCO PO author Dr. Timothy Showalter at Artera and University of Virginia shares insights into his JCO PO article, " Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer " . Host Dr. Rafeh Naqash and Dr. Showalter discuss how multimodal AI as a prognostic marker in nonmetastatic castration-resistant prostate cancer may serve as a predictive biomarker with high-risk patients der...
In this JCO Precision Oncology Article Insights episode, Natalie DelRocco summarizes " Digital Pathology–Based Multimodal Artificial Intelligence Scores and Outcomes in a Randomized Phase III Trial in Men With Nonmetastatic Castration-Resistant Prostate Cancer " by Felix Y. Feng, et al published January 31, 2025. Come back for the next episode where JCO Precision Oncology Conversations host, Dr. Rafeh Naqash interviews the author of the JCO PO article discussed, Dr. Tim Showalter. TRANSCRIPT Nat...
In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes " Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies. " by Dr. Ludmila Papusha et al. published on July 08, 2024. TRANSCRIPT Jiasen He: Hello and welcome to JCO Precision Oncology Article Insights . I'm your host Jiasen He, a JCO Journal' s Editorial Fellow. Today, I will provide a summary on " Midline Low-Grade Gliomas of Early Childhood: Focus on Targeted Therapies. " This is an observational s...
JCO PO author Dr. Hatim Husain at University of California San Diego, shares insights into his JCO PO article, "A dagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non–Small Cell Lung Cancer: A Case Series and Literature Review ", one of the top downloaded articles of 2024. Host Dr. Rafeh Naqash and Dr. Husain discuss how to utilize real-world and clinical trial data to discern the safety of adagrasib (another KRASG12C inhibitor), following sotorasib dis...
